This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by De Clercq, E
Right arrow Articles by Datema, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by De Clercq, E
Right arrow Articles by Datema, R

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1994 April; 38(4): 668-674

Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100.

E De Clercq, N Yamamoto, R Pauwels, J Balzarini, M Witvrouw, K De Vreese, Z Debyser, B Rosenwirth, P Peichl and R Datema

Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium.

ABSTRACT

Bicyclams, in which the cyclam (1,4,8,11-tetraazacyclotetradecane) moieties are tethered via an aliphatic bridge (i.e., propylene, as in JM2763) are potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) (E. De Clercq, N. Yamamoto, R. Pauwels, M. Baba, D. Schols, H. Nakashima, J. Balzarini, Z. Debyser, B. A. Murrer, D. Schwartz, D. Thornton, G. Bridger, S. Fricker, G. Henson, M. Abrams, and D. Picker, Proc. Natl. Acad. Sci. USA 89:5286-5290, 1992). We have now found that the bicyclam JM3100, in which the cyclam moieties are tethered by an aromatic bridge [i.e., phenylenebis(methylene)], inhibits the replication of various HIV-1 and HIV-2 strains in various cell lines at a 50% effective concentration (EC50) of 1 to 10 ng/ml, which is about 100-fold lower than the concentration required for JM2763 to inhibit HIV replication and at least 100,000-fold lower than the cytotoxic concentration (> 500 micrograms/ml). In primary T4 lymphocytes or primary monocytes, JM3100 proved inhibitory to HIV-1(IIIB) and several clinical HIV-1 isolates at an EC50 of less than 1 ng/ml. On the basis of time-of-addition experiments, JM3100 appeared to interact with a viral uncoating event, and this was further corroborated by an uncoating assay in which RNase sensitivity of [5-3H]uridine-labeled virions was monitored. In addition, but possibly mechanistically related, JM3100 blocks formation of infectious particles. JM3100 was also found to interfere directly with virus-induced syncytium formation, albeit at a higher concentration (1 to 2 microgram/ml) than that required for inhibition of viral replication. Following subcutaneous injection of 10 mg of JM3100 per kg of body weight to rabbits, anti-HIV activity was detected in serum corresponding to serum drug levels exceeding for at least 6 h by >100-fold the EC(50) required to inhibit HIV replication in vitro. When combined with either 3'-azido-2',3' -dideoxythymidine or 2',3' -dideoxyinosine, JM3100 achieved a additive inhibition of HIV replication, and when repeatedly subcultivated in the presence of JM3100, the virus remained sensitive to the compound for at least 30 passages (120 days) in cell culture.

Antimicrob Agents Chemother. 1994 April; 38(4): 668-674




This article has been cited by other articles:

  • McElrath, M. J., Ballweber, L., Terker, A., Kreger, A., Sakchalathorn, P., Robinson, B., Fialkow, M., Lentz, G., Hladik, F. (2010). Ex Vivo Comparison of Microbicide Efficacies for Preventing HIV-1 Genomic Integration in Intraepithelial Vaginal Cells. Antimicrob. Agents Chemother. 54: 763-772 [Abstract] [Full Text]  
  • Jekle, A., Chhabra, M., Lochner, A., Meier, S., Chow, E., Brandt, M., Sankuratri, S., Cammack, N., Heilek, G. (2010). Epitope Switching as a Novel Escape Mechanism of HIV to CCR5 Monoclonal Antibodies. Antimicrob. Agents Chemother. 54: 734-741 [Abstract] [Full Text]  
  • Takehisa, J., Kraus, M. H., Ayouba, A., Bailes, E., Van Heuverswyn, F., Decker, J. M., Li, Y., Rudicell, R. S., Learn, G. H., Neel, C., Ngole, E. M., Shaw, G. M., Peeters, M., Sharp, P. M., Hahn, B. H. (2009). Origin and Biology of Simian Immunodeficiency Virus in Wild-Living Western Gorillas. J. Virol. 83: 1635-1648 [Abstract] [Full Text]  
  • Harrison, J. E., Lynch, J. B., Sierra, L.-J., Blackburn, L. A., Ray, N., Collman, R. G., Doms, R. W. (2008). Baseline Resistance of Primary Human Immunodeficiency Virus Type 1 Strains to the CXCR4 Inhibitor AMD3100. J. Virol. 82: 11695-11704 [Abstract] [Full Text]  
  • Sundstrom, M., White, R. L., de Parseval, A., Sastry, K. J., Morris, G., Grant, C. K., Elder, J. H. (2008). Mapping of the CXCR4 Binding Site within Variable Region 3 of the Feline Immunodeficiency Virus Surface Glycoprotein. J. Virol. 82: 9134-9142 [Abstract] [Full Text]  
  • Nakata, H., Steinberg, S. M., Koh, Y., Maeda, K., Takaoka, Y., Tamamura, H., Fujii, N., Mitsuya, H. (2008). Potent Synergistic Anti-Human Immunodeficiency Virus (HIV) Effects Using Combinations of the CCR5 Inhibitor Aplaviroc with Other Anti-HIV Drugs. Antimicrob. Agents Chemother. 52: 2111-2119 [Abstract] [Full Text]  
  • Readinger, J. A., Schiralli, G. M., Jiang, J.-K., Thomas, C. J., August, A., Henderson, A. J., Schwartzberg, P. L. (2008). Selective targeting of ITK blocks multiple steps of HIV replication. Proc. Natl. Acad. Sci. USA 105: 6684-6689 [Abstract] [Full Text]  
  • Pacheco, B., Basmaciogullari, S., LaBonte, J. A., Xiang, S.-H., Sodroski, J. (2008). Adaptation of the Human Immunodeficiency Virus Type 1 Envelope Glycoproteins to New World Monkey Receptors. J. Virol. 82: 346-357 [Abstract] [Full Text]  
  • Rosenkilde, M. M., Gerlach, L.-O., Hatse, S., Skerlj, R. T., Schols, D., Bridger, G. J., Schwartz, T. W. (2007). Molecular Mechanism of Action of Monocyclam Versus Bicyclam Non-peptide Antagonists in the CXCR4 Chemokine Receptor. J. Biol. Chem. 282: 27354-27365 [Abstract] [Full Text]  
  • Daelemans, D., Lu, R., De Clercq, E., Engelman, A. (2007). Characterization of a Replication-Competent, Integrase-Defective Human Immunodeficiency Virus (HIV)/Simian Virus 40 Chimera as a Powerful Tool for the Discovery and Validation of HIV Integrase Inhibitors. J. Virol. 81: 4381-4385 [Abstract] [Full Text]  
  • Melikyan, G. B., Egelhofer, M., von Laer, D. (2006). Membrane-Anchored Inhibitory Peptides Capture Human Immunodeficiency Virus Type 1 gp41 Conformations That Engage the Target Membrane prior to Fusion. J. Virol. 80: 3249-3258 [Abstract] [Full Text]  
  • Ji, C., Zhang, J., Cammack, N., Sankuratri, S. (2006). Development of a Novel Dual CCR5-Dependent and CXCR4-Dependent Cell-Cell Fusion Assay System with Inducible gp160 Expression. J Biomol Screen 11: 65-74 [Abstract]  
  • Ghaffari, G., Tuttle, D. L., Briggs, D., Burkhardt, B. R., Bhatt, D., Andiman, W. A., Sleasman, J. W., Goodenow, M. M. (2005). Complex Determinants in Human Immunodeficiency Virus Type 1 Envelope gp120 Mediate CXCR4-Dependent Infection of Macrophages. J. Virol. 79: 13250-13261 [Abstract] [Full Text]  
  • Mkrtchyan, S. R., Markosyan, R. M., Eadon, M. T., Moore, J. P., Melikyan, G. B., Cohen, F. S. (2005). Ternary Complex Formation of Human Immunodeficiency Virus Type 1 Env, CD4, and Chemokine Receptor Captured as an Intermediate of Membrane Fusion. J. Virol. 79: 11161-11169 [Abstract] [Full Text]  
  • Yang, Q.-e., Stephen, A. G., Adelsberger, J. W., Roberts, P. E., Zhu, W., Currens, M. J., Feng, Y., Crise, B. J., Gorelick, R. J., Rein, A. R., Fisher, R. J., Shoemaker, R. H., Sei, S. (2005). Discovery of Small-Molecule Human Immunodeficiency Virus Type 1 Entry Inhibitors That Target the gp120-Binding Domain of CD4. J. Virol. 79: 6122-6133 [Abstract] [Full Text]  
  • Princen, K., Hatse, S., Vermeire, K., Aquaro, S., De Clercq, E., Gerlach, L.-O., Rosenkilde, M., Schwartz, T. W., Skerlj, R., Bridger, G., Schols, D. (2004). Inhibition of Human Immunodeficiency Virus Replication by a Dual CCR5/CXCR4 Antagonist. J. Virol. 78: 12996-13006 [Abstract] [Full Text]  
  • de Parseval, A., Chatterji, U., Sun, P., Elder, J. H. (2004). Feline immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptor. Proc. Natl. Acad. Sci. USA 101: 13044-13049 [Abstract] [Full Text]  
  • Pastore, C., Ramos, A., Mosier, D. E. (2004). Intrinsic Obstacles to Human Immunodeficiency Virus Type 1 Coreceptor Switching. J. Virol. 78: 7565-7574 [Abstract] [Full Text]  
  • Vermeire, K., Schols, D. (2003). Specific CD4 down-modulating compounds with potent anti-HIV activity. J. Leukoc. Biol. 74: 667-675 [Abstract] [Full Text]  
  • Fikkert, V., Cherepanov, P., Van Laethem, K., Hantson, A., Van Remoortel, B., Pannecouque, C., De Clercq, E., Debyser, Z., Vandamme, A.-M., Witvrouw, M. (2002). env Chimeric Virus Technology for Evaluating Human Immunodeficiency Virus Susceptibility to Entry Inhibitors. Antimicrob. Agents Chemother. 46: 3954-3962 [Abstract] [Full Text]  
  • Matthys, P., Hatse, S., Vermeire, K., Wuyts, A., Bridger, G., Henson, G. W., De Clercq, E., Billiau, A., Schols, D. (2001). AMD3100, a Potent and Specific Antagonist of the Stromal Cell-Derived Factor-1 Chemokine Receptor CXCR4, Inhibits Autoimmune Joint Inflammation in IFN-{gamma} Receptor-Deficient Mice. J. Immunol. 167: 4686-4692 [Abstract] [Full Text]  
  • Hatse, S., Princen, K., Gerlach, L.-O., Bridger, G., Henson, G., De Clercq, E., Schwartz, T. W., Schols, D. (2001). Mutation of Asp171 and Asp262 of the Chemokine Receptor CXCR4 Impairs Its Coreceptor Function for Human Immunodeficiency Virus-1 Entry and Abrogates the Antagonistic Activity of AMD3100. Mol. Pharmacol. 60: 164-173 [Abstract] [Full Text]  
  • Hendrix, C. W., Flexner, C., MacFarland, R. T., Giandomenico, C., Fuchs, E. J., Redpath, E., Bridger, G., Henson, G. W. (2000). Pharmacokinetics and Safety of AMD-3100, a Novel Antagonist of the CXCR-4 Chemokine Receptor, in Human Volunteers. Antimicrob. Agents Chemother. 44: 1667-1673 [Abstract] [Full Text]  
  • De Clercq, E. (2000). Inhibition of HIV Infection by Bicyclams, Highly Potent and Specific CXCR4 Antagonists. Mol. Pharmacol. 57: 833-839 [Abstract] [Full Text]  
  • Blanco, J., Barretina, J., Henson, G., Bridger, G., De Clercq, E., Clotet, B., Este, J. A. (2000). The CXCR4 Antagonist AMD3100 Efficiently Inhibits Cell-Surface-Expressed Human Immunodeficiency Virus Type 1 Envelope-Induced Apoptosis. Antimicrob. Agents Chemother. 44: 51-56 [Abstract] [Full Text]  
  • Egberink, H. F., De Clercq, E., Van Vliet, A. L. W., Balzarini, J., Bridger, G. J., Henson, G., Horzinek, M. C., Schols, D. (1999). Bicyclams, Selective Antagonists of the Human Chemokine Receptor CXCR4, Potently Inhibit Feline Immunodeficiency Virus Replication. J. Virol. 73: 6346-6352 [Abstract] [Full Text]  
  • Arakaki, R., Tamamura, H., Premanathan, M., Kanbara, K., Ramanan, S., Mochizuki, K., Baba, M., Fujii, N., Nakashima, H. (1999). T134, a Small-Molecule CXCR4 Inhibitor, Has No Cross-Drug Resistance with AMD3100, a CXCR4 Antagonist with a Different Structure. J. Virol. 73: 1719-1723 [Abstract] [Full Text]  
  • Este, J. A., Cabrera, C., De Clercq, E., Struyf, S., Van Damme, J., Bridger, G., Skerlj, R. T., Abrams, M. J., Henson, G., Gutierrez, A., Clotet, B., Schols, D. (1999). Activity of Different Bicyclam Derivatives against Human Immunodeficiency Virus Depends on Their Interaction with the CXCR4 Chemokine Receptor. Mol. Pharmacol. 55: 67-73 [Abstract] [Full Text]  
  • Labrosse, B., Brelot, A., Heveker, N., Sol, N., Schols, D., De Clercq, E., Alizon, M. (1998). Determinants for Sensitivity of Human Immunodeficiency Virus Coreceptor CXCR4 to the Bicyclam AMD3100. J. Virol. 72: 6381-6388 [Abstract] [Full Text]  
  • Schols, D., Este, J. A., Cabrera, C., De Clercq, E. (1998). T-Cell-Line-Tropic Human Immunodeficiency Virus Type 1 That Is Made Resistant to Stromal Cell-Derived Factor 1alpha Contains Mutations in the Envelope gp120 but Does Not Show a Switch in Coreceptor Use. J. Virol. 72: 4032-4037 [Abstract] [Full Text]  
  • Schols, D., Struyf, S., Damme, J. V., Este, J. A., Henson, G., Clercq, E. D. (1997). Inhibition of T-tropic HIV Strains by Selective Antagonization of the Chemokine Receptor CXCR4. JEM 186: 1383-1388 [Abstract] [Full Text]  
  • Este, J. A., Schols, D., De Vreese, K., Van Laethem, K., Vandamme, A.-M., Desmyter, J., De Clercq, E. (1997). Development of Resistance of Human Immunodeficiency Virus Type 1 to Dextran Sulfate Associated with the Emergence of Specific Mutations in the Envelope gp120 Glycoprotein. Mol. Pharmacol. 52: 98-104 [Abstract] [Full Text]  
  • Gerlach, L. O., Skerlj, R. T., Bridger, G. J., Schwartz, T. W. (2001). Molecular Interactions of Cyclam and Bicyclam Non-peptide Antagonists with the CXCR4 Chemokine Receptor. J. Biol. Chem. 276: 14153-14160 [Abstract] [Full Text]  
  • Maeda, K., Yoshimura, K., Shibayama, S., Habashita, H., Tada, H., Sagawa, K., Miyakawa, T., Aoki, M., Fukushima, D., Mitsuya, H. (2001). Novel Low Molecular Weight Spirodiketopiperazine Derivatives Potently Inhibit R5 HIV-1 Infection through Their Antagonistic Effects on CCR5. J. Biol. Chem. 276: 35194-35200 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»